Pharma Major Lupin Limited (Lupin) announced the appointment of J. Alan Butcher as Chief Corporate Development Officer. Alan will lead Lupin’s Global Corporate Development efforts and will be responsible for the Company’s Global M&A, Business Development and Licensing functions. In this role, Alan will be responsible for leading the company’s overall business development efforts, with a focus on continuing to build Lupin’s Specialty and Novel products business.

Commenting on the appointment, Vinita Gupta, Chief Executive Officer, Lupin said, “We are very pleased to welcome Alan to our leadership team. Alan’s experience in leading portfolio strategy and business development in specialty and big pharma companies, will help us enhance our plans to evolve our Specialty and Novel products business and optimize our capital allocation efforts to drive long term growth and value”

Alan brings extensive strategic, business development, technical and scientific experience to Lupin from over 30 years in the pharmaceutical industry. He joins Lupin from AMAG Pharmaceuticals where he served as Executive Vice President and Chief Business Officer. Prior to AMAG, he served as Senior Vice President, licensing and business development for Purdue Pharma. Prior to Purdue, he led a global business development team and was responsible for identifying, evaluating and negotiating expansion opportunities at Shire Pharmaceuticals. Earlier in his career, Alan conducted scientific research in areas of molecular genetics, virology and cardiovascular drug discovery.

Alan holds a Bachelor of Science in Clinical Microbiology and a Master of Arts in Biology with a concentration in Molecular Biology and Genetics from West Chester University of Pennsylvania. He is also an MBA graduate from Cornell University’s Johnson Graduate School of Management.

Alan will be based at Naples, Florida and he will report to Vinita Gupta, CEO.